[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f6-IYg9vWQJqyNyvXEwqrSY4Sk53VYQNxrvti9CVROfU":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":84,"rows":91},"Sinocelltech Ltd.",[4],77,false,25,23,72339,29,1,[14,17,20,23,26,28,31,33],{"name":15,"count":16},"COVID-19",17,{"name":18,"count":19},"SARS-CoV-2 Infection",11,{"name":21,"count":22},"Hemophilia A",5,{"name":24,"count":25},"Head and Neck Squamous Cell Carcinoma",3,{"name":27,"count":25},"Advanced Malignant Solid Tumor",{"name":29,"count":30},"Metastatic Colorectal Cancer",2,{"name":32,"count":30},"B-cell Non Hodgkin's Lymphoma",{"name":34,"count":30},"Advanced Malignant Solid Tumours",[36,41,46,51,56,61,66,71,76,80],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT04709328","To Evaluate SCTA01 Treatment of High-risk Outpatients With COVID-19","2022-01-01","SCTA01",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT06041061","A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years","2024-03","Recombinant 14-Valent Human Papillomavirus Vaccine（Insect Cell）",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT06252298","A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies","2025-08-28","SCTC21C",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT06801509","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster Vaccine","2025-11-10","Recombinant Herpes Zoster Vaccine (SCTV04C) Low-Dose",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT06769984","A Study of SCTT11 in Healthy Participants and Participants with Thyroid Eye Disease.","2026-06-24","SCTT11",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT06197009","Efficacy and Safety of SCT650C in Participants With Axial Spondyloarthritis","2026-07-01","SCT650C",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT06672536","Multicenter, Phase I\u002FII Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD","2026-09-23","SCT520FF",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT06318884","A First-in-human Study of SCTB35 in Patients With Relapse\u002FRefractory B-cell Non-Hodgkin Lymphoma","2026-10","SCTB35",{"nctId":77,"briefTitle":78,"date":79,"intervention":65},"NCT07244510","Efficacy and Safety of SCT650C in Participants With Moderate to Severe Hidradenitis Suppurativa","2027-03-12",{"nctId":81,"briefTitle":82,"date":83,"intervention":50},"NCT07538154","A Clinica Study of SCTC21C in Participants With Systemic Lupus Erythematosus","2027-04",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,160,218,255,277,299,321,378,406,424,442,460,478,496,521,545,584,618,661,686,710,735,760,778,796,814,838,861,879,901,943,1061,1127,1166,1196,1245,1276,1312,1349,1387,1409,1435,1453,1471,1489,1507,1525,1543,1561,1579,1597,1622,1640,1698,1735,1757,1779,1803,1828,1846,1864,1887,1918,1936,1954,1972,1990,2008,2026,2044,2062,2080,2102,2128,2152,2170,2188],{"intervention":50,"totalTrials":22,"cells":93},{"EARLY_PHASE1":94,"PHASE1":97,"PHASE2":108,"PHASE3":130,"PHASE4":156,"NA":158},{"trials":95,"activeCount":96},[],0,{"trials":98,"activeCount":12,"soonestReadout":49},[99],{"nctId":47,"briefTitle":48,"status":100,"phases":101,"primaryCompletion":49,"completion":102,"start":103,"enrollment":104,"conditions":105,"interventions":107},"RECRUITING",[86],"2027-02-28","2024-02-28",74,[106],"Relapsed or Refractory Hematologic Malignancies",[50],{"trials":109,"activeCount":30,"soonestReadout":83},[110,119],{"nctId":81,"briefTitle":82,"status":111,"phases":112,"primaryCompletion":83,"completion":113,"start":114,"enrollment":115,"conditions":116,"interventions":118},"NOT_YET_RECRUITING",[86,87],"2028-04","2026-04",159,[117],"Systemic Lupus Erythematosus (SLE)",[50],{"nctId":120,"briefTitle":121,"status":111,"phases":122,"primaryCompletion":123,"completion":124,"start":125,"enrollment":126,"conditions":127,"interventions":129},"NCT06774664","A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases",[86,87],"2027-09","2029-03","2025-01",99,[128],"IgA Nephropathy",[50],{"trials":131,"activeCount":30,"soonestReadout":136},[132,146],{"nctId":133,"briefTitle":134,"status":100,"phases":135,"primaryCompletion":136,"completion":137,"start":138,"enrollment":139,"conditions":140,"interventions":142},"NCT07297329","A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant",[88],"2027-12","2028-12","2025-12-29",292,[141],"Multiple Myeloma (MM)",[50,143,144,145],"Bortezomib","Lenalidomide","Dexamethasone",{"nctId":147,"briefTitle":148,"status":100,"phases":149,"primaryCompletion":136,"completion":137,"start":150,"enrollment":151,"conditions":152,"interventions":154},"NCT07388602","A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)",[88],"2026-01-08",90,[153],"Amyloidosis",[50,143,145,155],"Cyclophosphamide",{"trials":157,"activeCount":96},[],{"trials":159,"activeCount":96},[],{"intervention":75,"totalTrials":161,"cells":162},4,{"EARLY_PHASE1":163,"PHASE1":165,"PHASE2":174,"PHASE3":187,"PHASE4":214,"NA":216},{"trials":164,"activeCount":96},[],{"trials":166,"activeCount":12,"soonestReadout":74},[167],{"nctId":72,"briefTitle":73,"status":111,"phases":168,"primaryCompletion":74,"completion":136,"start":169,"enrollment":170,"conditions":171,"interventions":173},[86],"2024-04",76,[172],"Non-Hodgkin Lymphoma, B-cell",[75],{"trials":175,"activeCount":12,"soonestReadout":180},[176],{"nctId":177,"briefTitle":178,"status":100,"phases":179,"primaryCompletion":180,"completion":181,"start":182,"enrollment":183,"conditions":184,"interventions":186},"NCT06841042","A Study of SCTB35 in Patients with Systemic Lupus Erythematosus",[86,87],"2027-05","2028-10","2025-02",168,[185],"System Lupus Erythematosus",[75],{"trials":188,"activeCount":30,"soonestReadout":193},[189,203],{"nctId":190,"briefTitle":191,"status":111,"phases":192,"primaryCompletion":193,"completion":194,"start":195,"enrollment":196,"conditions":197,"interventions":199},"NCT07570823","A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",[88],"2027-11","2029-04","2026-05",101,[198],"DLBCL - Diffuse Large B Cell Lymphoma",[75,200,201,202],"Rituxumab","Gemcitabine","Oxaliplatin",{"nctId":204,"briefTitle":205,"status":111,"phases":206,"primaryCompletion":207,"completion":208,"start":195,"enrollment":209,"conditions":210,"interventions":212},"NCT07562022","A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma",[88],"2028-05","2029-06",93,[211],"Follicular Lymphoma (FL)",[75,213,144],"Rituximab",{"trials":215,"activeCount":96},[],{"trials":217,"activeCount":96},[],{"intervention":219,"totalTrials":30,"cells":220},"SCTB14",{"EARLY_PHASE1":221,"PHASE1":223,"PHASE2":225,"PHASE3":237,"PHASE4":251,"NA":253},{"trials":222,"activeCount":96},[],{"trials":224,"activeCount":96},[],{"trials":226,"activeCount":12,"soonestReadout":231},[227],{"nctId":228,"briefTitle":229,"status":111,"phases":230,"primaryCompletion":231,"completion":232,"start":233,"enrollment":234,"conditions":235,"interventions":236},"NCT06304818","Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB14 in Adult Patients With Advanced Malignant Solid Tumours.",[86,87],"2027-12-30","2028-12-30","2024-04-30",515,[34],[219],{"trials":238,"activeCount":12,"soonestReadout":243},[239],{"nctId":240,"briefTitle":241,"status":100,"phases":242,"primaryCompletion":243,"completion":244,"start":245,"enrollment":246,"conditions":247,"interventions":249},"NCT07362459","A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.",[88],"2027-07","2029-09","2025-12-30",246,[248],"Non-Small Cell Lung Carcinoma (NSCLC)",[219,250],"Pembrolizumab",{"trials":252,"activeCount":96},[],{"trials":254,"activeCount":96},[],{"intervention":143,"totalTrials":30,"cells":256},{"EARLY_PHASE1":257,"PHASE1":259,"PHASE2":261,"PHASE3":263,"PHASE4":273,"NA":275},{"trials":258,"activeCount":96},[],{"trials":260,"activeCount":96},[],{"trials":262,"activeCount":96},[],{"trials":264,"activeCount":30,"soonestReadout":136},[265,269],{"nctId":133,"briefTitle":134,"status":100,"phases":266,"primaryCompletion":136,"completion":137,"start":138,"enrollment":139,"conditions":267,"interventions":268},[88],[141],[50,143,144,145],{"nctId":147,"briefTitle":148,"status":100,"phases":270,"primaryCompletion":136,"completion":137,"start":150,"enrollment":151,"conditions":271,"interventions":272},[88],[153],[50,143,145,155],{"trials":274,"activeCount":96},[],{"trials":276,"activeCount":96},[],{"intervention":144,"totalTrials":30,"cells":278},{"EARLY_PHASE1":279,"PHASE1":281,"PHASE2":283,"PHASE3":285,"PHASE4":295,"NA":297},{"trials":280,"activeCount":96},[],{"trials":282,"activeCount":96},[],{"trials":284,"activeCount":96},[],{"trials":286,"activeCount":30,"soonestReadout":136},[287,291],{"nctId":133,"briefTitle":134,"status":100,"phases":288,"primaryCompletion":136,"completion":137,"start":138,"enrollment":139,"conditions":289,"interventions":290},[88],[141],[50,143,144,145],{"nctId":204,"briefTitle":205,"status":111,"phases":292,"primaryCompletion":207,"completion":208,"start":195,"enrollment":209,"conditions":293,"interventions":294},[88],[211],[75,213,144],{"trials":296,"activeCount":96},[],{"trials":298,"activeCount":96},[],{"intervention":145,"totalTrials":30,"cells":300},{"EARLY_PHASE1":301,"PHASE1":303,"PHASE2":305,"PHASE3":307,"PHASE4":317,"NA":319},{"trials":302,"activeCount":96},[],{"trials":304,"activeCount":96},[],{"trials":306,"activeCount":96},[],{"trials":308,"activeCount":30,"soonestReadout":136},[309,313],{"nctId":133,"briefTitle":134,"status":100,"phases":310,"primaryCompletion":136,"completion":137,"start":138,"enrollment":139,"conditions":311,"interventions":312},[88],[141],[50,143,144,145],{"nctId":147,"briefTitle":148,"status":100,"phases":314,"primaryCompletion":136,"completion":137,"start":150,"enrollment":151,"conditions":315,"interventions":316},[88],[153],[50,143,145,155],{"trials":318,"activeCount":96},[],{"trials":320,"activeCount":96},[],{"intervention":40,"totalTrials":161,"cells":322},{"EARLY_PHASE1":323,"PHASE1":325,"PHASE2":338,"PHASE3":340,"PHASE4":374,"NA":376},{"trials":324,"activeCount":96},[],{"trials":326,"activeCount":96},[327],{"nctId":328,"briefTitle":329,"status":330,"phases":331,"primaryCompletion":332,"completion":332,"start":333,"enrollment":334,"conditions":335,"interventions":337},"NCT04483375","Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects","COMPLETED",[86],"2020-11-17","2020-07-24",33,[336],"Coronavirus Disease 2019(COVID-19)",[40],{"trials":339,"activeCount":96},[],{"trials":341,"activeCount":12,"soonestReadout":39},[342,350,362],{"nctId":37,"briefTitle":38,"status":111,"phases":343,"primaryCompletion":39,"completion":344,"start":345,"enrollment":346,"conditions":347,"interventions":349},[87,88],"2022-03-01","2021-03-28",690,[15,348],"SARS-CoV-2",[40],{"nctId":351,"briefTitle":352,"status":353,"phases":354,"primaryCompletion":355,"completion":356,"start":357,"enrollment":358,"conditions":359,"interventions":361},"NCT04644185","The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19","TERMINATED",[87,88],"2021-12-29","2022-02-11","2021-03-27",102,[360],"Covid19",[40],{"nctId":363,"briefTitle":364,"status":365,"phases":366,"primaryCompletion":367,"completion":368,"start":369,"enrollment":370,"conditions":371,"interventions":372},"NCT04683328","The Safety and Efficacy of SCTA01 Against COVID-19 in Patients Admitted to High Dependence or Intensive Care","UNKNOWN",[87,88],"2021-05-25","2021-11-25","2021-02-25",560,[360],[40,373],"SCTA01 Placebo",{"trials":375,"activeCount":96},[],{"trials":377,"activeCount":96},[],{"intervention":213,"totalTrials":30,"cells":379},{"EARLY_PHASE1":380,"PHASE1":382,"PHASE2":384,"PHASE3":396,"PHASE4":402,"NA":404},{"trials":381,"activeCount":96},[],{"trials":383,"activeCount":96},[],{"trials":385,"activeCount":96},[386],{"nctId":387,"briefTitle":388,"status":365,"phases":389,"primaryCompletion":390,"completion":390,"start":391,"enrollment":392,"conditions":393,"interventions":394},"NCT02456207","A Pharmacokinetic Study Comparing SCT400 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma",[87],"2015-12","2015-05",80,[32],[395,213],"SCT400",{"trials":397,"activeCount":12,"soonestReadout":207},[398],{"nctId":204,"briefTitle":205,"status":111,"phases":399,"primaryCompletion":207,"completion":208,"start":195,"enrollment":209,"conditions":400,"interventions":401},[88],[211],[75,213,144],{"trials":403,"activeCount":96},[],{"trials":405,"activeCount":96},[],{"intervention":250,"totalTrials":12,"cells":407},{"EARLY_PHASE1":408,"PHASE1":410,"PHASE2":412,"PHASE3":414,"PHASE4":420,"NA":422},{"trials":409,"activeCount":96},[],{"trials":411,"activeCount":96},[],{"trials":413,"activeCount":96},[],{"trials":415,"activeCount":12,"soonestReadout":243},[416],{"nctId":240,"briefTitle":241,"status":100,"phases":417,"primaryCompletion":243,"completion":244,"start":245,"enrollment":246,"conditions":418,"interventions":419},[88],[248],[219,250],{"trials":421,"activeCount":96},[],{"trials":423,"activeCount":96},[],{"intervention":200,"totalTrials":12,"cells":425},{"EARLY_PHASE1":426,"PHASE1":428,"PHASE2":430,"PHASE3":432,"PHASE4":438,"NA":440},{"trials":427,"activeCount":96},[],{"trials":429,"activeCount":96},[],{"trials":431,"activeCount":96},[],{"trials":433,"activeCount":12,"soonestReadout":193},[434],{"nctId":190,"briefTitle":191,"status":111,"phases":435,"primaryCompletion":193,"completion":194,"start":195,"enrollment":196,"conditions":436,"interventions":437},[88],[198],[75,200,201,202],{"trials":439,"activeCount":96},[],{"trials":441,"activeCount":96},[],{"intervention":201,"totalTrials":12,"cells":443},{"EARLY_PHASE1":444,"PHASE1":446,"PHASE2":448,"PHASE3":450,"PHASE4":456,"NA":458},{"trials":445,"activeCount":96},[],{"trials":447,"activeCount":96},[],{"trials":449,"activeCount":96},[],{"trials":451,"activeCount":12,"soonestReadout":193},[452],{"nctId":190,"briefTitle":191,"status":111,"phases":453,"primaryCompletion":193,"completion":194,"start":195,"enrollment":196,"conditions":454,"interventions":455},[88],[198],[75,200,201,202],{"trials":457,"activeCount":96},[],{"trials":459,"activeCount":96},[],{"intervention":202,"totalTrials":12,"cells":461},{"EARLY_PHASE1":462,"PHASE1":464,"PHASE2":466,"PHASE3":468,"PHASE4":474,"NA":476},{"trials":463,"activeCount":96},[],{"trials":465,"activeCount":96},[],{"trials":467,"activeCount":96},[],{"trials":469,"activeCount":12,"soonestReadout":193},[470],{"nctId":190,"briefTitle":191,"status":111,"phases":471,"primaryCompletion":193,"completion":194,"start":195,"enrollment":196,"conditions":472,"interventions":473},[88],[198],[75,200,201,202],{"trials":475,"activeCount":96},[],{"trials":477,"activeCount":96},[],{"intervention":155,"totalTrials":12,"cells":479},{"EARLY_PHASE1":480,"PHASE1":482,"PHASE2":484,"PHASE3":486,"PHASE4":492,"NA":494},{"trials":481,"activeCount":96},[],{"trials":483,"activeCount":96},[],{"trials":485,"activeCount":96},[],{"trials":487,"activeCount":12,"soonestReadout":136},[488],{"nctId":147,"briefTitle":148,"status":100,"phases":489,"primaryCompletion":136,"completion":137,"start":150,"enrollment":151,"conditions":490,"interventions":491},[88],[153],[50,143,145,155],{"trials":493,"activeCount":96},[],{"trials":495,"activeCount":96},[],{"intervention":497,"totalTrials":12,"cells":498},"SCT800 prophylaxis and treatment for bleeding events",{"EARLY_PHASE1":499,"PHASE1":501,"PHASE2":503,"PHASE3":505,"PHASE4":517,"NA":519},{"trials":500,"activeCount":96},[],{"trials":502,"activeCount":96},[],{"trials":504,"activeCount":96},[],{"trials":506,"activeCount":12,"soonestReadout":511},[507],{"nctId":508,"briefTitle":509,"status":100,"phases":510,"primaryCompletion":511,"completion":511,"start":512,"enrollment":513,"conditions":514,"interventions":516},"NCT07437404","Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients.",[88],"2028-12-26","2024-04-26",36,[515],"Haemophilia A",[497],{"trials":518,"activeCount":96},[],{"trials":520,"activeCount":96},[],{"intervention":45,"totalTrials":12,"cells":522},{"EARLY_PHASE1":523,"PHASE1":525,"PHASE2":527,"PHASE3":529,"PHASE4":541,"NA":543},{"trials":524,"activeCount":96},[],{"trials":526,"activeCount":96},[],{"trials":528,"activeCount":96},[],{"trials":530,"activeCount":12,"soonestReadout":44},[531],{"nctId":42,"briefTitle":43,"status":532,"phases":533,"primaryCompletion":44,"completion":534,"start":535,"enrollment":536,"conditions":537,"interventions":540},"ACTIVE_NOT_RECRUITING",[88],"2028-08","2023-08-13",18000,[538,539],"HPV InfectioN","HPV-Related Carcinoma",[45],{"trials":542,"activeCount":96},[],{"trials":544,"activeCount":96},[],{"intervention":65,"totalTrials":25,"cells":546},{"EARLY_PHASE1":547,"PHASE1":549,"PHASE2":561,"PHASE3":578,"PHASE4":580,"NA":582},{"trials":548,"activeCount":96},[],{"trials":550,"activeCount":96},[551],{"nctId":552,"briefTitle":553,"status":365,"phases":554,"primaryCompletion":555,"completion":44,"start":556,"enrollment":557,"conditions":558,"interventions":560},"NCT05894707","Evaluate the Safety and Tolerability of SCT650C in Healthy Volunteers",[86],"2023-11","2023-06",32,[559],"Autoimmune Disease",[65],{"trials":562,"activeCount":30,"soonestReadout":64},[563,571],{"nctId":77,"briefTitle":78,"status":100,"phases":564,"primaryCompletion":79,"completion":565,"start":566,"enrollment":567,"conditions":568,"interventions":570},[87],"2028-02-16","2025-12-16",60,[569],"Hidradenitis Suppurativa (HS)",[65],{"nctId":62,"briefTitle":63,"status":111,"phases":572,"primaryCompletion":64,"completion":573,"start":574,"enrollment":183,"conditions":575,"interventions":577},[87],"2026-08-01","2024-07-01",[576],"Axial Spondyloarthritis",[65],{"trials":579,"activeCount":96},[],{"trials":581,"activeCount":96},[],{"trials":583,"activeCount":96},[],{"intervention":585,"totalTrials":30,"cells":586},"SCTB41",{"EARLY_PHASE1":587,"PHASE1":589,"PHASE2":591,"PHASE3":612,"PHASE4":614,"NA":616},{"trials":588,"activeCount":96},[],{"trials":590,"activeCount":96},[],{"trials":592,"activeCount":30,"soonestReadout":606},[593,602],{"nctId":594,"briefTitle":595,"status":111,"phases":596,"primaryCompletion":181,"completion":597,"start":195,"enrollment":151,"conditions":598,"interventions":600},"NCT07609251","A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study Ongoing）",[87],"2029-07",[599],"NSCLC (Advanced Non-small Cell Lung Cancer)",[585,601],"docetaxel",{"nctId":603,"briefTitle":604,"status":100,"phases":605,"primaryCompletion":606,"completion":607,"start":608,"enrollment":609,"conditions":610,"interventions":611},"NCT06600022","Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours.",[86,87],"2027-04-30","2028-04-30","2024-10-10",441,[34],[585],{"trials":613,"activeCount":96},[],{"trials":615,"activeCount":96},[],{"trials":617,"activeCount":96},[],{"intervention":601,"totalTrials":25,"cells":619},{"EARLY_PHASE1":620,"PHASE1":622,"PHASE2":637,"PHASE3":643,"PHASE4":657,"NA":659},{"trials":621,"activeCount":96},[],{"trials":623,"activeCount":96},[624],{"nctId":625,"briefTitle":626,"status":365,"phases":627,"primaryCompletion":628,"completion":628,"start":629,"enrollment":630,"conditions":631,"interventions":633},"NCT05552807","SCT200 in Combination With SCT-I10A\u002FPaclitaxel\u002FDocetaxel in Recurrent\u002FMetastatic Head and Neck Squamous Cell Carcinoma",[86],"2023-09","2022-06-15",120,[632],"Head and Neck Squamous Carcinoma",[634,635,636,601],"SCT-I10A","SCT200","paclitaxel",{"trials":638,"activeCount":12,"soonestReadout":181},[639],{"nctId":594,"briefTitle":595,"status":111,"phases":640,"primaryCompletion":181,"completion":597,"start":195,"enrollment":151,"conditions":641,"interventions":642},[87],[599],[585,601],{"trials":644,"activeCount":96},[645],{"nctId":646,"briefTitle":647,"status":353,"phases":648,"primaryCompletion":649,"completion":649,"start":650,"enrollment":651,"conditions":652,"interventions":654},"NCT04171284","SCT-I10A or Placebo Plus Docetaxel With Previously Treated Squamous Cell Non-small Cell Lung Cancer",[88],"2023-02-23","2019-10-22",188,[653],"Squamous-cell Non-Small-cell Lung Cancer",[655,656],"SCT-I10","Docetaxel",{"trials":658,"activeCount":96},[],{"trials":660,"activeCount":96},[],{"intervention":662,"totalTrials":12,"cells":663},"SCTV02",{"EARLY_PHASE1":664,"PHASE1":666,"PHASE2":668,"PHASE3":680,"PHASE4":682,"NA":684},{"trials":665,"activeCount":96},[],{"trials":667,"activeCount":96},[],{"trials":669,"activeCount":12,"soonestReadout":674},[670],{"nctId":671,"briefTitle":672,"status":100,"phases":673,"primaryCompletion":674,"completion":674,"start":675,"enrollment":676,"conditions":677,"interventions":679},"NCT06754605","A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Respiratory Syncytial Virus Vaccine",[86,87],"2027-07-30","2025-02-06",480,[678],"Respiratory Syncytial Virus",[662],{"trials":681,"activeCount":96},[],{"trials":683,"activeCount":96},[],{"trials":685,"activeCount":96},[],{"intervention":687,"totalTrials":12,"cells":688},"SCTB39-1",{"EARLY_PHASE1":689,"PHASE1":691,"PHASE2":693,"PHASE3":704,"PHASE4":706,"NA":708},{"trials":690,"activeCount":96},[],{"trials":692,"activeCount":96},[],{"trials":694,"activeCount":12,"soonestReadout":699},[695],{"nctId":696,"briefTitle":697,"status":100,"phases":698,"primaryCompletion":699,"completion":699,"start":700,"enrollment":701,"conditions":702,"interventions":703},"NCT07050641","Phase I\u002FII Study of SCTB39-1 in Advanced Solid Tumours",[86,87],"2028-06-30","2025-06-23",110,[27],[687],{"trials":705,"activeCount":96},[],{"trials":707,"activeCount":96},[],{"trials":709,"activeCount":96},[],{"intervention":711,"totalTrials":12,"cells":712},"SCTB39G",{"EARLY_PHASE1":713,"PHASE1":715,"PHASE2":717,"PHASE3":729,"PHASE4":731,"NA":733},{"trials":714,"activeCount":96},[],{"trials":716,"activeCount":96},[],{"trials":718,"activeCount":12,"soonestReadout":723},[719],{"nctId":720,"briefTitle":721,"status":111,"phases":722,"primaryCompletion":723,"completion":724,"start":725,"enrollment":726,"conditions":727,"interventions":728},"NCT07077252","Phase I\u002FII Study of SCTB39G in Advanced Solid Tumours",[86,87],"2027-09-26","2027-10-17","2025-07-28",30,[27],[711],{"trials":730,"activeCount":96},[],{"trials":732,"activeCount":96},[],{"trials":734,"activeCount":96},[],{"intervention":55,"totalTrials":12,"cells":736},{"EARLY_PHASE1":737,"PHASE1":739,"PHASE2":741,"PHASE3":754,"PHASE4":756,"NA":758},{"trials":738,"activeCount":96},[],{"trials":740,"activeCount":96},[],{"trials":742,"activeCount":12,"soonestReadout":54},[743],{"nctId":52,"briefTitle":53,"status":111,"phases":744,"primaryCompletion":54,"completion":745,"start":746,"enrollment":747,"conditions":748,"interventions":750},[86,87],"2027-10-10","2025-02-15",540,[749],"Herpes Zoster",[55,751,752,753],"Recombinant Herpes Zoster Vaccine (SCTV04C) High-Dose","Shingrix®","Ganwei®",{"trials":755,"activeCount":96},[],{"trials":757,"activeCount":96},[],{"trials":759,"activeCount":96},[],{"intervention":751,"totalTrials":12,"cells":761},{"EARLY_PHASE1":762,"PHASE1":764,"PHASE2":766,"PHASE3":772,"PHASE4":774,"NA":776},{"trials":763,"activeCount":96},[],{"trials":765,"activeCount":96},[],{"trials":767,"activeCount":12,"soonestReadout":54},[768],{"nctId":52,"briefTitle":53,"status":111,"phases":769,"primaryCompletion":54,"completion":745,"start":746,"enrollment":747,"conditions":770,"interventions":771},[86,87],[749],[55,751,752,753],{"trials":773,"activeCount":96},[],{"trials":775,"activeCount":96},[],{"trials":777,"activeCount":96},[],{"intervention":752,"totalTrials":12,"cells":779},{"EARLY_PHASE1":780,"PHASE1":782,"PHASE2":784,"PHASE3":790,"PHASE4":792,"NA":794},{"trials":781,"activeCount":96},[],{"trials":783,"activeCount":96},[],{"trials":785,"activeCount":12,"soonestReadout":54},[786],{"nctId":52,"briefTitle":53,"status":111,"phases":787,"primaryCompletion":54,"completion":745,"start":746,"enrollment":747,"conditions":788,"interventions":789},[86,87],[749],[55,751,752,753],{"trials":791,"activeCount":96},[],{"trials":793,"activeCount":96},[],{"trials":795,"activeCount":96},[],{"intervention":753,"totalTrials":12,"cells":797},{"EARLY_PHASE1":798,"PHASE1":800,"PHASE2":802,"PHASE3":808,"PHASE4":810,"NA":812},{"trials":799,"activeCount":96},[],{"trials":801,"activeCount":96},[],{"trials":803,"activeCount":12,"soonestReadout":54},[804],{"nctId":52,"briefTitle":53,"status":111,"phases":805,"primaryCompletion":54,"completion":745,"start":746,"enrollment":747,"conditions":806,"interventions":807},[86,87],[749],[55,751,752,753],{"trials":809,"activeCount":96},[],{"trials":811,"activeCount":96},[],{"trials":813,"activeCount":96},[],{"intervention":815,"totalTrials":12,"cells":816},"SCTB41+SCTB39-1",{"EARLY_PHASE1":817,"PHASE1":819,"PHASE2":821,"PHASE3":832,"PHASE4":834,"NA":836},{"trials":818,"activeCount":96},[],{"trials":820,"activeCount":96},[],{"trials":822,"activeCount":12,"soonestReadout":827},[823],{"nctId":824,"briefTitle":825,"status":111,"phases":826,"primaryCompletion":827,"completion":827,"start":828,"enrollment":829,"conditions":830,"interventions":831},"NCT07594028","Phase I\u002FII Study of SCTB41 Plus SCTB39-1with or Without Standard Therapy in Advanced Solid Tumours",[86,87],"2029-05-30","2026-05-30",126,[27],[815],{"trials":833,"activeCount":96},[],{"trials":835,"activeCount":96},[],{"trials":837,"activeCount":96},[],{"intervention":70,"totalTrials":12,"cells":839},{"EARLY_PHASE1":840,"PHASE1":842,"PHASE2":844,"PHASE3":855,"PHASE4":857,"NA":859},{"trials":841,"activeCount":96},[],{"trials":843,"activeCount":96},[],{"trials":845,"activeCount":12,"soonestReadout":69},[846],{"nctId":67,"briefTitle":68,"status":100,"phases":847,"primaryCompletion":69,"completion":848,"start":849,"enrollment":850,"conditions":851,"interventions":853},[86,87],"2027-01-11","2024-11-26",82,[852],"nAMD",[70,70,70,854],"EYLEA 2 MG",{"trials":856,"activeCount":96},[],{"trials":858,"activeCount":96},[],{"trials":860,"activeCount":96},[],{"intervention":854,"totalTrials":12,"cells":862},{"EARLY_PHASE1":863,"PHASE1":865,"PHASE2":867,"PHASE3":873,"PHASE4":875,"NA":877},{"trials":864,"activeCount":96},[],{"trials":866,"activeCount":96},[],{"trials":868,"activeCount":12,"soonestReadout":69},[869],{"nctId":67,"briefTitle":68,"status":100,"phases":870,"primaryCompletion":69,"completion":848,"start":849,"enrollment":850,"conditions":871,"interventions":872},[86,87],[852],[70,70,70,854],{"trials":874,"activeCount":96},[],{"trials":876,"activeCount":96},[],{"trials":878,"activeCount":96},[],{"intervention":60,"totalTrials":12,"cells":880},{"EARLY_PHASE1":881,"PHASE1":883,"PHASE2":885,"PHASE3":895,"PHASE4":897,"NA":899},{"trials":882,"activeCount":96},[],{"trials":884,"activeCount":96},[],{"trials":886,"activeCount":12,"soonestReadout":59},[887],{"nctId":57,"briefTitle":58,"status":111,"phases":888,"primaryCompletion":59,"completion":889,"start":890,"enrollment":891,"conditions":892,"interventions":894},[86,87],"2028-09-19","2025-02-19",100,[893],"TED",[60],{"trials":896,"activeCount":96},[],{"trials":898,"activeCount":96},[],{"trials":900,"activeCount":96},[],{"intervention":902,"totalTrials":25,"cells":903},"Recombinant Human Coagulation FVIII",{"EARLY_PHASE1":904,"PHASE1":906,"PHASE2":908,"PHASE3":910,"PHASE4":930,"NA":941},{"trials":905,"activeCount":96},[],{"trials":907,"activeCount":96},[],{"trials":909,"activeCount":96},[],{"trials":911,"activeCount":96},[912,921],{"nctId":913,"briefTitle":914,"status":330,"phases":915,"primaryCompletion":916,"completion":916,"start":917,"enrollment":918,"conditions":919,"interventions":920},"NCT03815318","Evaluation of SCT800 in Prophylaxis Therapy on Previous Treated Patients With Severe Hemophilia A",[88],"2020-01-16","2019-01-21",73,[21],[902],{"nctId":922,"briefTitle":923,"status":365,"phases":924,"primaryCompletion":925,"completion":925,"start":926,"enrollment":927,"conditions":928,"interventions":929},"NCT03947320","Safety,Efficacy and Pharmacokinetics Evaluation of SCT800 in Previously Treated Paediatric Patients With Severe Haemophilia A.",[88],"2020-09-20","2019-12-20",70,[21],[902],{"trials":931,"activeCount":96},[932],{"nctId":933,"briefTitle":934,"status":365,"phases":935,"primaryCompletion":936,"completion":936,"start":937,"enrollment":938,"conditions":939,"interventions":940},"NCT03947567","Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia A Patients.",[89],"2025-04-01","2019-07-26",240,[21],[902],{"trials":942,"activeCount":96},[],{"intervention":944,"totalTrials":945,"cells":946},"SCTV01E",10,{"EARLY_PHASE1":947,"PHASE1":949,"PHASE2":951,"PHASE3":1025,"PHASE4":1057,"NA":1059},{"trials":948,"activeCount":96},[],{"trials":950,"activeCount":96},[],{"trials":952,"activeCount":96},[953,965,975,988,995,1006,1017],{"nctId":954,"briefTitle":955,"status":365,"phases":956,"primaryCompletion":957,"completion":958,"start":959,"enrollment":960,"conditions":961,"interventions":963},"NCT05238441","A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E in Population Aged ≥18 Years Previously Fully Vaccinated With mRNA COVID-19 Vaccine",[87],"2022-06-01","2023-05-01","2022-03-20",360,[15,962],"Sars-CoV-2 Infection",[944,964,944,964],"Comirnaty",{"nctId":966,"briefTitle":967,"status":330,"phases":968,"primaryCompletion":969,"completion":969,"start":970,"enrollment":971,"conditions":972,"interventions":974},"NCT05652543","A PhaseⅡ Study to Evaluate the Safety & Immunogenicity of SARS-CoV-2 Alpha\u002FBeta\u002FDelta\u002FOmicron Variants COVID-19 Vaccine",[87],"2024-01-15","2023-01-05",518,[973],"COVID-19 Pandemic",[944],{"nctId":976,"briefTitle":977,"status":978,"phases":979,"primaryCompletion":980,"completion":981,"start":982,"enrollment":96,"conditions":983,"interventions":984},"NCT05308602","A Study to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E (Two Recombinant Protein COVID-19 Vaccines) in Population Aged ≥12 Years","WITHDRAWN",[87],"2022-08-01","2023-08-01","2022-04-01",[15,18],[985,985,985,944,944,944,986,986,986,987,987,987],"SCTV01C","mRNA vaccine manufactured by Pfizer or Moderna","Sinopharm inactivated COVID-19 vaccine",{"nctId":989,"briefTitle":990,"status":365,"phases":991,"primaryCompletion":980,"completion":981,"start":982,"enrollment":992,"conditions":993,"interventions":994},"NCT05239806","A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E in Population Aged ≥12 Years Previously Fully Vaccinated With Inactivated COVID-19 Vaccine",[87],400,[15,18],[985,944,987,964,944],{"nctId":996,"briefTitle":997,"status":365,"phases":998,"primaryCompletion":999,"completion":1000,"start":1001,"enrollment":1002,"conditions":1003,"interventions":1004},"NCT05933512","A Study to Evaluate the Immunogenicity and Safety of A Recombinant Protein COVID-19 Vaccine as Booster Vaccines",[87],"2023-12-10","2024-11-10","2023-08-10",600,[15,18],[1005,944],"SCTV01E-2",{"nctId":1007,"briefTitle":1008,"status":365,"phases":1009,"primaryCompletion":1010,"completion":1011,"start":1012,"enrollment":1013,"conditions":1014,"interventions":1015},"NCT05345873","A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine as a Booster Dose in Population Aged 12-17 Years",[87],"2022-10-01","2023-04-01","2022-07-01",300,[15,18],[944,1016],"mRNA-1273",{"nctId":1018,"briefTitle":1019,"status":365,"phases":1020,"primaryCompletion":1021,"completion":1022,"start":1012,"enrollment":992,"conditions":1023,"interventions":1024},"NCT05329051","A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged ≥18 Years",[87],"2022-09-01","2023-03-01",[18,15],[944,964],{"trials":1026,"activeCount":96},[1027,1036,1048],{"nctId":1028,"briefTitle":1029,"status":365,"phases":1030,"primaryCompletion":1031,"completion":958,"start":1032,"enrollment":1033,"conditions":1034,"interventions":1035},"NCT05323461","A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Years as Booster Vaccines",[88],"2022-10-28","2022-05-30",1800,[15,18],[985,944,987,964],{"nctId":1037,"briefTitle":1038,"status":365,"phases":1039,"primaryCompletion":1040,"completion":1041,"start":1042,"enrollment":1043,"conditions":1044,"interventions":1046},"NCT05683561","A Phase III Clinical Trial to Evaluate the Efficacy and Safety of SCTV01E in Healthy People",[88],"2023-08-25","2024-08-25","2023-01-25",6000,[1045],"COVID-19 SARS-CoV-2 Infection",[1047,944],"CoronaVac",{"nctId":1049,"briefTitle":1050,"status":365,"phases":1051,"primaryCompletion":1052,"completion":169,"start":1053,"enrollment":1054,"conditions":1055,"interventions":1056},"NCT05308576","A Study to Evaluate the Efficacy and Safety of SCTV01E (a COVID-19 Vaccine) in Population Aged ≥18 Years",[88],"2023-05-10","2022-12-26",10000,[15,18],[944],{"trials":1058,"activeCount":96},[],{"trials":1060,"activeCount":96},[],{"intervention":985,"totalTrials":1062,"cells":1063},8,{"EARLY_PHASE1":1064,"PHASE1":1066,"PHASE2":1068,"PHASE3":1117,"PHASE4":1123,"NA":1125},{"trials":1065,"activeCount":96},[],{"trials":1067,"activeCount":96},[],{"trials":1069,"activeCount":96},[1070,1078,1082,1086,1095,1102,1108],{"nctId":1071,"briefTitle":1072,"status":365,"phases":1073,"primaryCompletion":957,"completion":1074,"start":1075,"enrollment":1013,"conditions":1076,"interventions":1077},"NCT05043311","The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With mRNA COVID-19 Vaccine.",[86,87],"2023-01-01","2021-12-22",[15,18],[985],{"nctId":976,"briefTitle":977,"status":978,"phases":1079,"primaryCompletion":980,"completion":981,"start":982,"enrollment":96,"conditions":1080,"interventions":1081},[87],[15,18],[985,985,985,944,944,944,986,986,986,987,987,987],{"nctId":989,"briefTitle":990,"status":365,"phases":1083,"primaryCompletion":980,"completion":981,"start":982,"enrollment":992,"conditions":1084,"interventions":1085},[87],[15,18],[985,944,987,964,944],{"nctId":1087,"briefTitle":1088,"status":978,"phases":1089,"primaryCompletion":1012,"completion":1090,"start":1091,"enrollment":96,"conditions":1092,"interventions":1094},"NCT05239975","A Study of the Immunogenicity and Safety of SCTV01C in Population Aged ≥12 Years and Previously Vaccinated With Inactivated COVID-19 Vaccine",[87],"2023-02-01","2022-04-25",[15,1093],"SARS-CoV2 Infection",[985,964],{"nctId":1096,"briefTitle":1097,"status":365,"phases":1098,"primaryCompletion":1012,"completion":1099,"start":959,"enrollment":1002,"conditions":1100,"interventions":1101},"NCT05238454","A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C in Population Aged ≥18 Years and Previously Fully Vaccinated With COVID-19 Vaccine",[87],"2022-12-01",[15,18],[985,987,964],{"nctId":1103,"briefTitle":1104,"status":365,"phases":1105,"primaryCompletion":957,"completion":1074,"start":1075,"enrollment":1013,"conditions":1106,"interventions":1107},"NCT05043285","The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With Inactivated COVID-19 Vaccine.",[86,87],[15,18],[985],{"nctId":1109,"briefTitle":1110,"status":330,"phases":1111,"primaryCompletion":1112,"completion":1112,"start":1113,"enrollment":1114,"conditions":1115,"interventions":1116},"NCT05148091","The Safety, Tolerability and Immunogenicity of COVID-19 Vaccine (SCTV01C) in Healthy, Unvaccinated Adults",[86,87],"2023-08-04","2021-12-01",478,[15],[985],{"trials":1118,"activeCount":96},[1119],{"nctId":1028,"briefTitle":1029,"status":365,"phases":1120,"primaryCompletion":1031,"completion":958,"start":1032,"enrollment":1033,"conditions":1121,"interventions":1122},[88],[15,18],[985,944,987,964],{"trials":1124,"activeCount":96},[],{"trials":1126,"activeCount":96},[],{"intervention":964,"totalTrials":1128,"cells":1129},6,{"EARLY_PHASE1":1130,"PHASE1":1132,"PHASE2":1134,"PHASE3":1156,"PHASE4":1162,"NA":1164},{"trials":1131,"activeCount":96},[],{"trials":1133,"activeCount":96},[],{"trials":1135,"activeCount":96},[1136,1140,1144,1148,1152],{"nctId":954,"briefTitle":955,"status":365,"phases":1137,"primaryCompletion":957,"completion":958,"start":959,"enrollment":960,"conditions":1138,"interventions":1139},[87],[15,962],[944,964,944,964],{"nctId":989,"briefTitle":990,"status":365,"phases":1141,"primaryCompletion":980,"completion":981,"start":982,"enrollment":992,"conditions":1142,"interventions":1143},[87],[15,18],[985,944,987,964,944],{"nctId":1087,"briefTitle":1088,"status":978,"phases":1145,"primaryCompletion":1012,"completion":1090,"start":1091,"enrollment":96,"conditions":1146,"interventions":1147},[87],[15,1093],[985,964],{"nctId":1096,"briefTitle":1097,"status":365,"phases":1149,"primaryCompletion":1012,"completion":1099,"start":959,"enrollment":1002,"conditions":1150,"interventions":1151},[87],[15,18],[985,987,964],{"nctId":1018,"briefTitle":1019,"status":365,"phases":1153,"primaryCompletion":1021,"completion":1022,"start":1012,"enrollment":992,"conditions":1154,"interventions":1155},[87],[18,15],[944,964],{"trials":1157,"activeCount":96},[1158],{"nctId":1028,"briefTitle":1029,"status":365,"phases":1159,"primaryCompletion":1031,"completion":958,"start":1032,"enrollment":1033,"conditions":1160,"interventions":1161},[88],[15,18],[985,944,987,964],{"trials":1163,"activeCount":96},[],{"trials":1165,"activeCount":96},[],{"intervention":987,"totalTrials":161,"cells":1167},{"EARLY_PHASE1":1168,"PHASE1":1170,"PHASE2":1172,"PHASE3":1186,"PHASE4":1192,"NA":1194},{"trials":1169,"activeCount":96},[],{"trials":1171,"activeCount":96},[],{"trials":1173,"activeCount":96},[1174,1178,1182],{"nctId":976,"briefTitle":977,"status":978,"phases":1175,"primaryCompletion":980,"completion":981,"start":982,"enrollment":96,"conditions":1176,"interventions":1177},[87],[15,18],[985,985,985,944,944,944,986,986,986,987,987,987],{"nctId":989,"briefTitle":990,"status":365,"phases":1179,"primaryCompletion":980,"completion":981,"start":982,"enrollment":992,"conditions":1180,"interventions":1181},[87],[15,18],[985,944,987,964,944],{"nctId":1096,"briefTitle":1097,"status":365,"phases":1183,"primaryCompletion":1012,"completion":1099,"start":959,"enrollment":1002,"conditions":1184,"interventions":1185},[87],[15,18],[985,987,964],{"trials":1187,"activeCount":96},[1188],{"nctId":1028,"briefTitle":1029,"status":365,"phases":1189,"primaryCompletion":1031,"completion":958,"start":1032,"enrollment":1033,"conditions":1190,"interventions":1191},[88],[15,18],[985,944,987,964],{"trials":1193,"activeCount":96},[],{"trials":1195,"activeCount":96},[],{"intervention":634,"totalTrials":161,"cells":1197},{"EARLY_PHASE1":1198,"PHASE1":1200,"PHASE2":1225,"PHASE3":1227,"PHASE4":1241,"NA":1243},{"trials":1199,"activeCount":96},[],{"trials":1201,"activeCount":96},[1202,1211,1215],{"nctId":1203,"briefTitle":1204,"status":365,"phases":1205,"primaryCompletion":980,"completion":1099,"start":1206,"enrollment":567,"conditions":1207,"interventions":1210},"NCT04229537","Study of SCT-I10A Combined SCT200 or SCT-I10A Combined SCT200 Plus Chemotherapy in ESCC and CRC",[86],"2020-03-01",[1208,1209],"Esophageal Squamous Cell Carcinoma","Colorectal Cancer",[634,635],{"nctId":625,"briefTitle":626,"status":365,"phases":1212,"primaryCompletion":628,"completion":628,"start":629,"enrollment":630,"conditions":1213,"interventions":1214},[86],[632],[634,635,636,601],{"nctId":1216,"briefTitle":1217,"status":365,"phases":1218,"primaryCompletion":1219,"completion":1219,"start":1220,"enrollment":1221,"conditions":1222,"interventions":1224},"NCT03821363","Safety, Tolerability, Pharmacokinetics and Efficacy of SCT-I10A in Patients With Advanced Solid Tumors or Lymphoma",[86],"2020-07","2018-12-13",206,[1223],"Advanced Solid Tumors or Lymphoma",[634],{"trials":1226,"activeCount":96},[],{"trials":1228,"activeCount":96},[1229],{"nctId":1230,"briefTitle":1231,"status":365,"phases":1232,"primaryCompletion":169,"completion":1233,"start":1234,"enrollment":1235,"conditions":1236,"interventions":1238},"NCT04560894","SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma",[87,88],"2024-09","2020-11-11",405,[1237],"Hepatocellular Carcinoma",[634,1239,1240],"SCT510","Sorafenib 200mg",{"trials":1242,"activeCount":96},[],{"trials":1244,"activeCount":96},[],{"intervention":1239,"totalTrials":30,"cells":1246},{"EARLY_PHASE1":1247,"PHASE1":1249,"PHASE2":1251,"PHASE3":1253,"PHASE4":1272,"NA":1274},{"trials":1248,"activeCount":96},[],{"trials":1250,"activeCount":96},[],{"trials":1252,"activeCount":96},[],{"trials":1254,"activeCount":96},[1255,1259],{"nctId":1230,"briefTitle":1231,"status":365,"phases":1256,"primaryCompletion":169,"completion":1233,"start":1234,"enrollment":1235,"conditions":1257,"interventions":1258},[87,88],[1237],[634,1239,1240],{"nctId":1260,"briefTitle":1261,"status":365,"phases":1262,"primaryCompletion":1263,"completion":1264,"start":1265,"enrollment":370,"conditions":1266,"interventions":1268},"NCT03792074","To Evaluate the Efficacy and Safety of SCT510 in the Treatment of Non-small Cell Lung Cancer",[88],"2021-05","2022-01","2019-02",[1267],"Non-squamous Cell Non-small Cell Lung Cancer",[1239,1269,1270,1271],"Bevacizumab","Paclitaxel","Carboplatin",{"trials":1273,"activeCount":96},[],{"trials":1275,"activeCount":96},[],{"intervention":1277,"totalTrials":30,"cells":1278},"SCT800",{"EARLY_PHASE1":1279,"PHASE1":1281,"PHASE2":1294,"PHASE3":1296,"PHASE4":1308,"NA":1310},{"trials":1280,"activeCount":96},[],{"trials":1282,"activeCount":96},[1283],{"nctId":1284,"briefTitle":1285,"status":365,"phases":1286,"primaryCompletion":1287,"completion":1288,"start":1289,"enrollment":1290,"conditions":1291,"interventions":1292},"NCT02888223","Pharmacokinetic Study of SCT800 in Previously Treated Patients With Hemophilia A",[86],"2017-02","2017-07","2016-09",16,[21],[1277,1293],"Xyntha",{"trials":1295,"activeCount":96},[],{"trials":1297,"activeCount":96},[1298],{"nctId":1299,"briefTitle":1300,"status":365,"phases":1301,"primaryCompletion":1302,"completion":1303,"start":1304,"enrollment":1305,"conditions":1306,"interventions":1307},"NCT02921945","Efficacy and Safety Study of SCT800 for On-demand Treatment With in Patients With Hemophilia A",[88],"2017-12","2018-06","2016-10",50,[21],[1277],{"trials":1309,"activeCount":96},[],{"trials":1311,"activeCount":96},[],{"intervention":1313,"totalTrials":30,"cells":1314},"SCT510A",{"EARLY_PHASE1":1315,"PHASE1":1317,"PHASE2":1319,"PHASE3":1332,"PHASE4":1345,"NA":1347},{"trials":1316,"activeCount":96},[],{"trials":1318,"activeCount":96},[],{"trials":1320,"activeCount":96},[1321],{"nctId":1322,"briefTitle":1323,"status":365,"phases":1324,"primaryCompletion":1325,"completion":1326,"start":1327,"enrollment":1328,"conditions":1329,"interventions":1331},"NCT04564937","The Study of Drug SCT510A in Patients With Wet Age-related Macular Degeneration (wAMD)",[86,87],"2022-04-30","2022-10-31","2020-11-06",66,[1330],"Wet Age-related Macular Degeneration",[1313],{"trials":1333,"activeCount":96},[1334],{"nctId":1335,"briefTitle":1336,"status":365,"phases":1337,"primaryCompletion":1338,"completion":1339,"start":1340,"enrollment":1341,"conditions":1342,"interventions":1343},"NCT05480293","This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD",[88],"2025-07-31","2025-08-31","2023-02-14",446,[1330],[1344,1313],"Ranibizumab",{"trials":1346,"activeCount":96},[],{"trials":1348,"activeCount":96},[],{"intervention":1350,"totalTrials":30,"cells":1351},"SCT630",{"EARLY_PHASE1":1352,"PHASE1":1354,"PHASE2":1367,"PHASE3":1369,"PHASE4":1383,"NA":1385},{"trials":1353,"activeCount":96},[],{"trials":1355,"activeCount":96},[1356],{"nctId":1357,"briefTitle":1358,"status":330,"phases":1359,"primaryCompletion":1360,"completion":1360,"start":1361,"enrollment":1362,"conditions":1363,"interventions":1365},"NCT03917628","Pharmacokinetics and Safety in Healthy Volunteers",[86],"2019-11-04","2019-05-29",146,[1364],"Healthy",[1350,1366],"adalimumab-EU source",{"trials":1368,"activeCount":96},[],{"trials":1370,"activeCount":96},[1371],{"nctId":1372,"briefTitle":1373,"status":365,"phases":1374,"primaryCompletion":1375,"completion":1376,"start":1377,"enrollment":1378,"conditions":1379,"interventions":1381},"NCT03927352","The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis",[88],"2021-12-31","2022-12-31","2019-09-05",330,[1380],"Psoriasis",[1350,1382],"Adalimumab",{"trials":1384,"activeCount":96},[],{"trials":1386,"activeCount":96},[],{"intervention":1270,"totalTrials":30,"cells":1388},{"EARLY_PHASE1":1389,"PHASE1":1391,"PHASE2":1397,"PHASE3":1399,"PHASE4":1405,"NA":1407},{"trials":1390,"activeCount":96},[],{"trials":1392,"activeCount":96},[1393],{"nctId":625,"briefTitle":626,"status":365,"phases":1394,"primaryCompletion":628,"completion":628,"start":629,"enrollment":630,"conditions":1395,"interventions":1396},[86],[632],[634,635,636,601],{"trials":1398,"activeCount":96},[],{"trials":1400,"activeCount":96},[1401],{"nctId":1260,"briefTitle":1261,"status":365,"phases":1402,"primaryCompletion":1263,"completion":1264,"start":1265,"enrollment":370,"conditions":1403,"interventions":1404},[88],[1267],[1239,1269,1270,1271],{"trials":1406,"activeCount":96},[],{"trials":1408,"activeCount":96},[],{"intervention":1410,"totalTrials":12,"cells":1411},"SCT400 plus CHOP",{"EARLY_PHASE1":1412,"PHASE1":1414,"PHASE2":1416,"PHASE3":1418,"PHASE4":1431,"NA":1433},{"trials":1413,"activeCount":96},[],{"trials":1415,"activeCount":96},[],{"trials":1417,"activeCount":96},[],{"trials":1419,"activeCount":96},[1420],{"nctId":1421,"briefTitle":1422,"status":365,"phases":1423,"primaryCompletion":1424,"completion":1425,"start":1426,"enrollment":1378,"conditions":1427,"interventions":1429},"NCT02772822","A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL Patients",[88],"2019-06","2019-12","2016-06",[1428],"Diffuse Large B Cell Lymphoma",[1410,1430],"Rituximab plus CHOP",{"trials":1432,"activeCount":96},[],{"trials":1434,"activeCount":96},[],{"intervention":1430,"totalTrials":12,"cells":1436},{"EARLY_PHASE1":1437,"PHASE1":1439,"PHASE2":1441,"PHASE3":1443,"PHASE4":1449,"NA":1451},{"trials":1438,"activeCount":96},[],{"trials":1440,"activeCount":96},[],{"trials":1442,"activeCount":96},[],{"trials":1444,"activeCount":96},[1445],{"nctId":1421,"briefTitle":1422,"status":365,"phases":1446,"primaryCompletion":1424,"completion":1425,"start":1426,"enrollment":1378,"conditions":1447,"interventions":1448},[88],[1428],[1410,1430],{"trials":1450,"activeCount":96},[],{"trials":1452,"activeCount":96},[],{"intervention":655,"totalTrials":12,"cells":1454},{"EARLY_PHASE1":1455,"PHASE1":1457,"PHASE2":1459,"PHASE3":1461,"PHASE4":1467,"NA":1469},{"trials":1456,"activeCount":96},[],{"trials":1458,"activeCount":96},[],{"trials":1460,"activeCount":96},[],{"trials":1462,"activeCount":96},[1463],{"nctId":646,"briefTitle":647,"status":353,"phases":1464,"primaryCompletion":649,"completion":649,"start":650,"enrollment":651,"conditions":1465,"interventions":1466},[88],[653],[655,656],{"trials":1468,"activeCount":96},[],{"trials":1470,"activeCount":96},[],{"intervention":1240,"totalTrials":12,"cells":1472},{"EARLY_PHASE1":1473,"PHASE1":1475,"PHASE2":1477,"PHASE3":1479,"PHASE4":1485,"NA":1487},{"trials":1474,"activeCount":96},[],{"trials":1476,"activeCount":96},[],{"trials":1478,"activeCount":96},[],{"trials":1480,"activeCount":96},[1481],{"nctId":1230,"briefTitle":1231,"status":365,"phases":1482,"primaryCompletion":169,"completion":1233,"start":1234,"enrollment":1235,"conditions":1483,"interventions":1484},[87,88],[1237],[634,1239,1240],{"trials":1486,"activeCount":96},[],{"trials":1488,"activeCount":96},[],{"intervention":1047,"totalTrials":12,"cells":1490},{"EARLY_PHASE1":1491,"PHASE1":1493,"PHASE2":1495,"PHASE3":1497,"PHASE4":1503,"NA":1505},{"trials":1492,"activeCount":96},[],{"trials":1494,"activeCount":96},[],{"trials":1496,"activeCount":96},[],{"trials":1498,"activeCount":96},[1499],{"nctId":1037,"briefTitle":1038,"status":365,"phases":1500,"primaryCompletion":1040,"completion":1041,"start":1042,"enrollment":1043,"conditions":1501,"interventions":1502},[88],[1045],[1047,944],{"trials":1504,"activeCount":96},[],{"trials":1506,"activeCount":96},[],{"intervention":1382,"totalTrials":12,"cells":1508},{"EARLY_PHASE1":1509,"PHASE1":1511,"PHASE2":1513,"PHASE3":1515,"PHASE4":1521,"NA":1523},{"trials":1510,"activeCount":96},[],{"trials":1512,"activeCount":96},[],{"trials":1514,"activeCount":96},[],{"trials":1516,"activeCount":96},[1517],{"nctId":1372,"briefTitle":1373,"status":365,"phases":1518,"primaryCompletion":1375,"completion":1376,"start":1377,"enrollment":1378,"conditions":1519,"interventions":1520},[88],[1380],[1350,1382],{"trials":1522,"activeCount":96},[],{"trials":1524,"activeCount":96},[],{"intervention":1269,"totalTrials":12,"cells":1526},{"EARLY_PHASE1":1527,"PHASE1":1529,"PHASE2":1531,"PHASE3":1533,"PHASE4":1539,"NA":1541},{"trials":1528,"activeCount":96},[],{"trials":1530,"activeCount":96},[],{"trials":1532,"activeCount":96},[],{"trials":1534,"activeCount":96},[1535],{"nctId":1260,"briefTitle":1261,"status":365,"phases":1536,"primaryCompletion":1263,"completion":1264,"start":1265,"enrollment":370,"conditions":1537,"interventions":1538},[88],[1267],[1239,1269,1270,1271],{"trials":1540,"activeCount":96},[],{"trials":1542,"activeCount":96},[],{"intervention":1271,"totalTrials":12,"cells":1544},{"EARLY_PHASE1":1545,"PHASE1":1547,"PHASE2":1549,"PHASE3":1551,"PHASE4":1557,"NA":1559},{"trials":1546,"activeCount":96},[],{"trials":1548,"activeCount":96},[],{"trials":1550,"activeCount":96},[],{"trials":1552,"activeCount":96},[1553],{"nctId":1260,"briefTitle":1261,"status":365,"phases":1554,"primaryCompletion":1263,"completion":1264,"start":1265,"enrollment":370,"conditions":1555,"interventions":1556},[88],[1267],[1239,1269,1270,1271],{"trials":1558,"activeCount":96},[],{"trials":1560,"activeCount":96},[],{"intervention":1344,"totalTrials":12,"cells":1562},{"EARLY_PHASE1":1563,"PHASE1":1565,"PHASE2":1567,"PHASE3":1569,"PHASE4":1575,"NA":1577},{"trials":1564,"activeCount":96},[],{"trials":1566,"activeCount":96},[],{"trials":1568,"activeCount":96},[],{"trials":1570,"activeCount":96},[1571],{"nctId":1335,"briefTitle":1336,"status":365,"phases":1572,"primaryCompletion":1338,"completion":1339,"start":1340,"enrollment":1341,"conditions":1573,"interventions":1574},[88],[1330],[1344,1313],{"trials":1576,"activeCount":96},[],{"trials":1578,"activeCount":96},[],{"intervention":373,"totalTrials":12,"cells":1580},{"EARLY_PHASE1":1581,"PHASE1":1583,"PHASE2":1585,"PHASE3":1587,"PHASE4":1593,"NA":1595},{"trials":1582,"activeCount":96},[],{"trials":1584,"activeCount":96},[],{"trials":1586,"activeCount":96},[],{"trials":1588,"activeCount":96},[1589],{"nctId":363,"briefTitle":364,"status":365,"phases":1590,"primaryCompletion":367,"completion":368,"start":369,"enrollment":370,"conditions":1591,"interventions":1592},[87,88],[360],[40,373],{"trials":1594,"activeCount":96},[],{"trials":1596,"activeCount":96},[],{"intervention":1598,"totalTrials":12,"cells":1599},"SCT-I10A+chemo",{"EARLY_PHASE1":1600,"PHASE1":1602,"PHASE2":1604,"PHASE3":1606,"PHASE4":1618,"NA":1620},{"trials":1601,"activeCount":96},[],{"trials":1603,"activeCount":96},[],{"trials":1605,"activeCount":96},[],{"trials":1607,"activeCount":96},[1608],{"nctId":1609,"briefTitle":1610,"status":365,"phases":1611,"primaryCompletion":1612,"completion":1613,"start":1614,"enrollment":1378,"conditions":1615,"interventions":1616},"NCT04146402","SCT-I10A Plus Standard Chemotherapy in First-line Recurrent\u002F Metastatic Head and Neck Squamous Cell Carcinoma",[88],"2022-01-29","2022-07-30","2019-12-31",[24],[1598,1617],"Placebos+chemo",{"trials":1619,"activeCount":96},[],{"trials":1621,"activeCount":96},[],{"intervention":1617,"totalTrials":12,"cells":1623},{"EARLY_PHASE1":1624,"PHASE1":1626,"PHASE2":1628,"PHASE3":1630,"PHASE4":1636,"NA":1638},{"trials":1625,"activeCount":96},[],{"trials":1627,"activeCount":96},[],{"trials":1629,"activeCount":96},[],{"trials":1631,"activeCount":96},[1632],{"nctId":1609,"briefTitle":1610,"status":365,"phases":1633,"primaryCompletion":1612,"completion":1613,"start":1614,"enrollment":1378,"conditions":1634,"interventions":1635},[88],[24],[1598,1617],{"trials":1637,"activeCount":96},[],{"trials":1639,"activeCount":96},[],{"intervention":635,"totalTrials":1128,"cells":1641},{"EARLY_PHASE1":1642,"PHASE1":1644,"PHASE2":1672,"PHASE3":1692,"PHASE4":1694,"NA":1696},{"trials":1643,"activeCount":96},[],{"trials":1645,"activeCount":96},[1646,1654,1658,1668],{"nctId":1647,"briefTitle":1648,"status":365,"phases":1649,"primaryCompletion":1425,"completion":1425,"start":1650,"enrollment":1305,"conditions":1651,"interventions":1653},"NCT03808701","Efficacy and Safety of SCT200 in Patients With Advanced Squamous Non-small Cell Lung Cancer",[86],"2019-03",[1652],"Advanced Squamous Non-small Cell Lung Cancer",[635],{"nctId":1203,"briefTitle":1204,"status":365,"phases":1655,"primaryCompletion":980,"completion":1099,"start":1206,"enrollment":567,"conditions":1656,"interventions":1657},[86],[1208,1209],[634,635],{"nctId":1659,"briefTitle":1660,"status":365,"phases":1661,"primaryCompletion":1662,"completion":1663,"start":1664,"enrollment":151,"conditions":1665,"interventions":1667},"NCT03692520","Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCT200 in Patients With Advanced Solid Tumors",[86],"2019-11-30","2020-04-30","2018-09-30",[1666],"Advanced Solid Tumors",[635],{"nctId":625,"briefTitle":626,"status":365,"phases":1669,"primaryCompletion":628,"completion":628,"start":629,"enrollment":630,"conditions":1670,"interventions":1671},[86],[632],[634,635,636,601],{"trials":1673,"activeCount":96},[1674,1683],{"nctId":1675,"briefTitle":1676,"status":365,"phases":1677,"primaryCompletion":1678,"completion":1614,"start":1679,"enrollment":726,"conditions":1680,"interventions":1682},"NCT03692689","Safety and Efficacy of SCT200 in Patients With Relapsed or Metastatic Triple Receptor Negative Breast Cancer",[87],"2019-09-30","2018-07-20",[1681],"Triple Negative Breast Neoplasms",[635],{"nctId":1684,"briefTitle":1685,"status":365,"phases":1686,"primaryCompletion":1687,"completion":1688,"start":1689,"enrollment":8,"conditions":1690,"interventions":1691},"NCT03874741","SCT200 Plus Platinum-based Chemotherapy in Head and Neck Squamous Cell Carcinoma",[87],"2020-06-30","2021-07-01","2019-05-21",[24],[635],{"trials":1693,"activeCount":96},[],{"trials":1695,"activeCount":96},[],{"trials":1697,"activeCount":96},[],{"intervention":1699,"totalTrials":30,"cells":1700},"SCT1000",{"EARLY_PHASE1":1701,"PHASE1":1703,"PHASE2":1716,"PHASE3":1729,"PHASE4":1731,"NA":1733},{"trials":1702,"activeCount":96},[],{"trials":1704,"activeCount":96},[1705],{"nctId":1706,"briefTitle":1707,"status":365,"phases":1708,"primaryCompletion":1709,"completion":1326,"start":1710,"enrollment":938,"conditions":1711,"interventions":1713},"NCT04921111","A Phase I Safty and Immunogenicity Study of SCT1000 in Healthy Women Aged 18 to 45 Years",[86],"2022-07-31","2021-07-02",[1712],"HPV Infection Vaccine Safety SCT1000",[1699,1714,1715],"Gardasil®9","Gardasil®",{"trials":1717,"activeCount":96},[1718],{"nctId":1719,"briefTitle":1720,"status":365,"phases":1721,"primaryCompletion":1722,"completion":1709,"start":1723,"enrollment":1033,"conditions":1724,"interventions":1728},"NCT05060484","A Phase II Study of SCT1000 in Healthy Women Aged 18 to 45 Years",[87],"2022-05-31","2021-10-19",[1725,1726,1727],"Interventional","Prevention","Randomized",[1699,1714,1715],{"trials":1730,"activeCount":96},[],{"trials":1732,"activeCount":96},[],{"trials":1734,"activeCount":96},[],{"intervention":1714,"totalTrials":30,"cells":1736},{"EARLY_PHASE1":1737,"PHASE1":1739,"PHASE2":1745,"PHASE3":1751,"PHASE4":1753,"NA":1755},{"trials":1738,"activeCount":96},[],{"trials":1740,"activeCount":96},[1741],{"nctId":1706,"briefTitle":1707,"status":365,"phases":1742,"primaryCompletion":1709,"completion":1326,"start":1710,"enrollment":938,"conditions":1743,"interventions":1744},[86],[1712],[1699,1714,1715],{"trials":1746,"activeCount":96},[1747],{"nctId":1719,"briefTitle":1720,"status":365,"phases":1748,"primaryCompletion":1722,"completion":1709,"start":1723,"enrollment":1033,"conditions":1749,"interventions":1750},[87],[1725,1726,1727],[1699,1714,1715],{"trials":1752,"activeCount":96},[],{"trials":1754,"activeCount":96},[],{"trials":1756,"activeCount":96},[],{"intervention":1715,"totalTrials":30,"cells":1758},{"EARLY_PHASE1":1759,"PHASE1":1761,"PHASE2":1767,"PHASE3":1773,"PHASE4":1775,"NA":1777},{"trials":1760,"activeCount":96},[],{"trials":1762,"activeCount":96},[1763],{"nctId":1706,"briefTitle":1707,"status":365,"phases":1764,"primaryCompletion":1709,"completion":1326,"start":1710,"enrollment":938,"conditions":1765,"interventions":1766},[86],[1712],[1699,1714,1715],{"trials":1768,"activeCount":96},[1769],{"nctId":1719,"briefTitle":1720,"status":365,"phases":1770,"primaryCompletion":1722,"completion":1709,"start":1723,"enrollment":1033,"conditions":1771,"interventions":1772},[87],[1725,1726,1727],[1699,1714,1715],{"trials":1774,"activeCount":96},[],{"trials":1776,"activeCount":96},[],{"trials":1778,"activeCount":96},[],{"intervention":1780,"totalTrials":12,"cells":1781},"Recombinant Anti-EGFR Monoclonal Antibody（SCT200）",{"EARLY_PHASE1":1782,"PHASE1":1784,"PHASE2":1786,"PHASE3":1797,"PHASE4":1799,"NA":1801},{"trials":1783,"activeCount":96},[],{"trials":1785,"activeCount":96},[],{"trials":1787,"activeCount":96},[1788],{"nctId":1789,"briefTitle":1790,"status":365,"phases":1791,"primaryCompletion":1792,"completion":1793,"start":1794,"enrollment":701,"conditions":1795,"interventions":1796},"NCT03405272","Safety and Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Wild-type RAS and BRAF mCRC",[87],"2018-12-01","2019-12-01","2018-02-12",[29],[1780],{"trials":1798,"activeCount":96},[],{"trials":1800,"activeCount":96},[],{"trials":1802,"activeCount":96},[],{"intervention":1804,"totalTrials":12,"cells":1805},"PD-1",{"EARLY_PHASE1":1806,"PHASE1":1808,"PHASE2":1810,"PHASE3":1822,"PHASE4":1824,"NA":1826},{"trials":1807,"activeCount":96},[],{"trials":1809,"activeCount":96},[],{"trials":1811,"activeCount":96},[1812],{"nctId":1813,"briefTitle":1814,"status":365,"phases":1815,"primaryCompletion":1816,"completion":1817,"start":1818,"enrollment":1819,"conditions":1820,"interventions":1821},"NCT04146181","Safety and Efficacy of SCT-I10A in Head and Neck Squamous Cell Carcinoma",[87],"2021-06-30","2021-09-30","2019-10-31",103,[24],[1804],{"trials":1823,"activeCount":96},[],{"trials":1825,"activeCount":96},[],{"trials":1827,"activeCount":96},[],{"intervention":986,"totalTrials":12,"cells":1829},{"EARLY_PHASE1":1830,"PHASE1":1832,"PHASE2":1834,"PHASE3":1840,"PHASE4":1842,"NA":1844},{"trials":1831,"activeCount":96},[],{"trials":1833,"activeCount":96},[],{"trials":1835,"activeCount":96},[1836],{"nctId":976,"briefTitle":977,"status":978,"phases":1837,"primaryCompletion":980,"completion":981,"start":982,"enrollment":96,"conditions":1838,"interventions":1839},[87],[15,18],[985,985,985,944,944,944,986,986,986,987,987,987],{"trials":1841,"activeCount":96},[],{"trials":1843,"activeCount":96},[],{"trials":1845,"activeCount":96},[],{"intervention":1005,"totalTrials":12,"cells":1847},{"EARLY_PHASE1":1848,"PHASE1":1850,"PHASE2":1852,"PHASE3":1858,"PHASE4":1860,"NA":1862},{"trials":1849,"activeCount":96},[],{"trials":1851,"activeCount":96},[],{"trials":1853,"activeCount":96},[1854],{"nctId":996,"briefTitle":997,"status":365,"phases":1855,"primaryCompletion":999,"completion":1000,"start":1001,"enrollment":1002,"conditions":1856,"interventions":1857},[87],[15,18],[1005,944],{"trials":1859,"activeCount":96},[],{"trials":1861,"activeCount":96},[],{"trials":1863,"activeCount":96},[],{"intervention":1865,"totalTrials":12,"cells":1866},"recombinant anti-EGFR monoclonal antibody",{"EARLY_PHASE1":1867,"PHASE1":1869,"PHASE2":1871,"PHASE3":1881,"PHASE4":1883,"NA":1885},{"trials":1868,"activeCount":96},[],{"trials":1870,"activeCount":96},[],{"trials":1872,"activeCount":96},[1873],{"nctId":1874,"briefTitle":1875,"status":365,"phases":1876,"primaryCompletion":1662,"completion":1877,"start":1878,"enrollment":1305,"conditions":1879,"interventions":1880},"NCT03817567","Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell Carcinoma",[86,87],"2020-05-31","2018-07-17",[1208],[1865],{"trials":1882,"activeCount":96},[],{"trials":1884,"activeCount":96},[],{"trials":1886,"activeCount":96},[],{"intervention":1888,"totalTrials":12,"cells":1889},"SCTV01E-1 on D0",{"EARLY_PHASE1":1890,"PHASE1":1892,"PHASE2":1894,"PHASE3":1912,"PHASE4":1914,"NA":1916},{"trials":1891,"activeCount":96},[],{"trials":1893,"activeCount":96},[],{"trials":1895,"activeCount":96},[1896],{"nctId":1897,"briefTitle":1898,"status":365,"phases":1899,"primaryCompletion":1900,"completion":1901,"start":1902,"enrollment":992,"conditions":1903,"interventions":1904},"NCT05522829","A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine SCTV01E-1 in Population Aged Above 18 Years",[87],"2022-12-15","2023-12-15","2022-10-15",[15,18],[1888,1905,1906,1907,1908,1909,1910,1911],"SCTV01E-1 on D28","SCTV01E-1 on D150","SCTV01E on D0","SCTV01E on D28","SCTV01E on D150","SCTV01E-1 on D120","SCTV01E on D120",{"trials":1913,"activeCount":96},[],{"trials":1915,"activeCount":96},[],{"trials":1917,"activeCount":96},[],{"intervention":1905,"totalTrials":12,"cells":1919},{"EARLY_PHASE1":1920,"PHASE1":1922,"PHASE2":1924,"PHASE3":1930,"PHASE4":1932,"NA":1934},{"trials":1921,"activeCount":96},[],{"trials":1923,"activeCount":96},[],{"trials":1925,"activeCount":96},[1926],{"nctId":1897,"briefTitle":1898,"status":365,"phases":1927,"primaryCompletion":1900,"completion":1901,"start":1902,"enrollment":992,"conditions":1928,"interventions":1929},[87],[15,18],[1888,1905,1906,1907,1908,1909,1910,1911],{"trials":1931,"activeCount":96},[],{"trials":1933,"activeCount":96},[],{"trials":1935,"activeCount":96},[],{"intervention":1906,"totalTrials":12,"cells":1937},{"EARLY_PHASE1":1938,"PHASE1":1940,"PHASE2":1942,"PHASE3":1948,"PHASE4":1950,"NA":1952},{"trials":1939,"activeCount":96},[],{"trials":1941,"activeCount":96},[],{"trials":1943,"activeCount":96},[1944],{"nctId":1897,"briefTitle":1898,"status":365,"phases":1945,"primaryCompletion":1900,"completion":1901,"start":1902,"enrollment":992,"conditions":1946,"interventions":1947},[87],[15,18],[1888,1905,1906,1907,1908,1909,1910,1911],{"trials":1949,"activeCount":96},[],{"trials":1951,"activeCount":96},[],{"trials":1953,"activeCount":96},[],{"intervention":1907,"totalTrials":12,"cells":1955},{"EARLY_PHASE1":1956,"PHASE1":1958,"PHASE2":1960,"PHASE3":1966,"PHASE4":1968,"NA":1970},{"trials":1957,"activeCount":96},[],{"trials":1959,"activeCount":96},[],{"trials":1961,"activeCount":96},[1962],{"nctId":1897,"briefTitle":1898,"status":365,"phases":1963,"primaryCompletion":1900,"completion":1901,"start":1902,"enrollment":992,"conditions":1964,"interventions":1965},[87],[15,18],[1888,1905,1906,1907,1908,1909,1910,1911],{"trials":1967,"activeCount":96},[],{"trials":1969,"activeCount":96},[],{"trials":1971,"activeCount":96},[],{"intervention":1908,"totalTrials":12,"cells":1973},{"EARLY_PHASE1":1974,"PHASE1":1976,"PHASE2":1978,"PHASE3":1984,"PHASE4":1986,"NA":1988},{"trials":1975,"activeCount":96},[],{"trials":1977,"activeCount":96},[],{"trials":1979,"activeCount":96},[1980],{"nctId":1897,"briefTitle":1898,"status":365,"phases":1981,"primaryCompletion":1900,"completion":1901,"start":1902,"enrollment":992,"conditions":1982,"interventions":1983},[87],[15,18],[1888,1905,1906,1907,1908,1909,1910,1911],{"trials":1985,"activeCount":96},[],{"trials":1987,"activeCount":96},[],{"trials":1989,"activeCount":96},[],{"intervention":1909,"totalTrials":12,"cells":1991},{"EARLY_PHASE1":1992,"PHASE1":1994,"PHASE2":1996,"PHASE3":2002,"PHASE4":2004,"NA":2006},{"trials":1993,"activeCount":96},[],{"trials":1995,"activeCount":96},[],{"trials":1997,"activeCount":96},[1998],{"nctId":1897,"briefTitle":1898,"status":365,"phases":1999,"primaryCompletion":1900,"completion":1901,"start":1902,"enrollment":992,"conditions":2000,"interventions":2001},[87],[15,18],[1888,1905,1906,1907,1908,1909,1910,1911],{"trials":2003,"activeCount":96},[],{"trials":2005,"activeCount":96},[],{"trials":2007,"activeCount":96},[],{"intervention":1910,"totalTrials":12,"cells":2009},{"EARLY_PHASE1":2010,"PHASE1":2012,"PHASE2":2014,"PHASE3":2020,"PHASE4":2022,"NA":2024},{"trials":2011,"activeCount":96},[],{"trials":2013,"activeCount":96},[],{"trials":2015,"activeCount":96},[2016],{"nctId":1897,"briefTitle":1898,"status":365,"phases":2017,"primaryCompletion":1900,"completion":1901,"start":1902,"enrollment":992,"conditions":2018,"interventions":2019},[87],[15,18],[1888,1905,1906,1907,1908,1909,1910,1911],{"trials":2021,"activeCount":96},[],{"trials":2023,"activeCount":96},[],{"trials":2025,"activeCount":96},[],{"intervention":1911,"totalTrials":12,"cells":2027},{"EARLY_PHASE1":2028,"PHASE1":2030,"PHASE2":2032,"PHASE3":2038,"PHASE4":2040,"NA":2042},{"trials":2029,"activeCount":96},[],{"trials":2031,"activeCount":96},[],{"trials":2033,"activeCount":96},[2034],{"nctId":1897,"briefTitle":1898,"status":365,"phases":2035,"primaryCompletion":1900,"completion":1901,"start":1902,"enrollment":992,"conditions":2036,"interventions":2037},[87],[15,18],[1888,1905,1906,1907,1908,1909,1910,1911],{"trials":2039,"activeCount":96},[],{"trials":2041,"activeCount":96},[],{"trials":2043,"activeCount":96},[],{"intervention":1016,"totalTrials":12,"cells":2045},{"EARLY_PHASE1":2046,"PHASE1":2048,"PHASE2":2050,"PHASE3":2056,"PHASE4":2058,"NA":2060},{"trials":2047,"activeCount":96},[],{"trials":2049,"activeCount":96},[],{"trials":2051,"activeCount":96},[2052],{"nctId":1007,"briefTitle":1008,"status":365,"phases":2053,"primaryCompletion":1010,"completion":1011,"start":1012,"enrollment":1013,"conditions":2054,"interventions":2055},[87],[15,18],[944,1016],{"trials":2057,"activeCount":96},[],{"trials":2059,"activeCount":96},[],{"trials":2061,"activeCount":96},[],{"intervention":395,"totalTrials":12,"cells":2063},{"EARLY_PHASE1":2064,"PHASE1":2066,"PHASE2":2068,"PHASE3":2074,"PHASE4":2076,"NA":2078},{"trials":2065,"activeCount":96},[],{"trials":2067,"activeCount":96},[],{"trials":2069,"activeCount":96},[2070],{"nctId":387,"briefTitle":388,"status":365,"phases":2071,"primaryCompletion":390,"completion":390,"start":391,"enrollment":392,"conditions":2072,"interventions":2073},[87],[32],[395,213],{"trials":2075,"activeCount":96},[],{"trials":2077,"activeCount":96},[],{"trials":2079,"activeCount":96},[],{"intervention":2081,"totalTrials":12,"cells":2082},"SCTA01 and SCTA01C",{"EARLY_PHASE1":2083,"PHASE1":2085,"PHASE2":2087,"PHASE3":2096,"PHASE4":2098,"NA":2100},{"trials":2084,"activeCount":96},[],{"trials":2086,"activeCount":96},[],{"trials":2088,"activeCount":96},[2089],{"nctId":2090,"briefTitle":2091,"status":978,"phases":2092,"primaryCompletion":1099,"completion":1099,"start":2093,"enrollment":96,"conditions":2094,"interventions":2095},"NCT05156645","A Study to Evaluate Efficacy and Safety of the Combination of SCTA01 & SCTA01C in Outpatients With COVID-19",[86,87],"2022-01-15",[15],[2081],{"trials":2097,"activeCount":96},[],{"trials":2099,"activeCount":96},[],{"trials":2101,"activeCount":96},[],{"intervention":2103,"totalTrials":12,"cells":2104},"Anti-EGFR monoclonal antibody",{"EARLY_PHASE1":2105,"PHASE1":2107,"PHASE2":2109,"PHASE3":2122,"PHASE4":2124,"NA":2126},{"trials":2106,"activeCount":96},[],{"trials":2108,"activeCount":96},[],{"trials":2110,"activeCount":96},[2111],{"nctId":2112,"briefTitle":2113,"status":365,"phases":2114,"primaryCompletion":2115,"completion":2116,"start":2117,"enrollment":2118,"conditions":2119,"interventions":2121},"NCT03713372","Safety and Efficacy of SCT200 in Head and Neck Squamous Cell Carcinoma",[87],"2020-02-11","2020-05-28","2018-11-28",40,[2120],"Head and Neck Cancer",[2103],{"trials":2123,"activeCount":96},[],{"trials":2125,"activeCount":96},[],{"trials":2127,"activeCount":96},[],{"intervention":2129,"totalTrials":12,"cells":2130},"Chimeric anti-CD20 monoclonal antibody",{"EARLY_PHASE1":2131,"PHASE1":2133,"PHASE2":2144,"PHASE3":2146,"PHASE4":2148,"NA":2150},{"trials":2132,"activeCount":96},[],{"trials":2134,"activeCount":96},[2135],{"nctId":2136,"briefTitle":2137,"status":330,"phases":2138,"primaryCompletion":2139,"completion":2139,"start":2140,"enrollment":2141,"conditions":2142,"interventions":2143},"NCT02206308","Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Chimeric Anti-CD20 Monoclonal Antibody in Patients With B-cell Non-Hodgkin's Lymphoma.",[86],"2013-07","2012-05",15,[32],[2129],{"trials":2145,"activeCount":96},[],{"trials":2147,"activeCount":96},[],{"trials":2149,"activeCount":96},[],{"trials":2151,"activeCount":96},[],{"intervention":1293,"totalTrials":12,"cells":2153},{"EARLY_PHASE1":2154,"PHASE1":2156,"PHASE2":2162,"PHASE3":2164,"PHASE4":2166,"NA":2168},{"trials":2155,"activeCount":96},[],{"trials":2157,"activeCount":96},[2158],{"nctId":1284,"briefTitle":1285,"status":365,"phases":2159,"primaryCompletion":1287,"completion":1288,"start":1289,"enrollment":1290,"conditions":2160,"interventions":2161},[86],[21],[1277,1293],{"trials":2163,"activeCount":96},[],{"trials":2165,"activeCount":96},[],{"trials":2167,"activeCount":96},[],{"trials":2169,"activeCount":96},[],{"intervention":1366,"totalTrials":12,"cells":2171},{"EARLY_PHASE1":2172,"PHASE1":2174,"PHASE2":2180,"PHASE3":2182,"PHASE4":2184,"NA":2186},{"trials":2173,"activeCount":96},[],{"trials":2175,"activeCount":96},[2176],{"nctId":1357,"briefTitle":1358,"status":330,"phases":2177,"primaryCompletion":1360,"completion":1360,"start":1361,"enrollment":1362,"conditions":2178,"interventions":2179},[86],[1364],[1350,1366],{"trials":2181,"activeCount":96},[],{"trials":2183,"activeCount":96},[],{"trials":2185,"activeCount":96},[],{"trials":2187,"activeCount":96},[],{"intervention":2189,"totalTrials":12,"cells":2190},"Recombinant full human Anti-EGFR Monoclonal Antibody",{"EARLY_PHASE1":2191,"PHASE1":2193,"PHASE2":2203,"PHASE3":2205,"PHASE4":2207,"NA":2209},{"trials":2192,"activeCount":96},[],{"trials":2194,"activeCount":96},[2195],{"nctId":2196,"briefTitle":2197,"status":365,"phases":2198,"primaryCompletion":390,"completion":390,"start":2199,"enrollment":2200,"conditions":2201,"interventions":2202},"NCT02211443","Safety, Tolerability and Pharmacokinetics of Recombinant Anti-epidermal Growth Factor Receptor(EGFR) Monoclonal Antibody in Patients With Metastatic Colorectal Cancer",[86],"2015-01",21,[29],[2189],{"trials":2204,"activeCount":96},[],{"trials":2206,"activeCount":96},[],{"trials":2208,"activeCount":96},[],{"trials":2210,"activeCount":96},[]]